News
Early intensive treatment of MS may benefit patients
Real-world population-based cohort study finds better outcomes at 5 years with first-line treatment with a high-efficacy therapy.
Real-world population-based cohort study finds better outcomes at 5 years with first-line treatment with a high-efficacy therapy.
BERLIN—Autologous hematopoietic stem cell transplantation (HSCT) could prevent disease activity and promote functional...
BERLIN—European registry data do not support the hypothesis that exposure to interferon beta before conception or during...
A post hoc analysis indicates that daclizumab beta has superior efficacy, compared with interferon beta-1a, regardless of patients’ baseline...
Patients with secondary progressive MS who are treated with rituximab off label may accrue less disability during follow-up, compared with matched...
Cladribine is not associated with an increased risk of infections or malignancy, and treatment-induced lymphopenia is transient.
Patients with food allergies had more MS relapses and greater odds of further nerve damage.
BERLIN –
Infusion of allogeneic BK virus-specific T cells may be an effective treatment for patients with progressive multifocal...
BERLIN – High-salt diets decimate Lactobacillus species, with downstream immune effects.
Rare but serious events described in multiple sclerosis patients given alemtuzumab (Lemtrada) prompts new warning.
BERLIN – Cognitive behavioral therapy carries the best evidence to treat MS-related fatigue.
The National Multiple Sclerosis (MS) Society has developed recommendations for the identification and management of...
BERLIN – Risk factors for higher disease activity include younger age at diagnosis, shorter disease duration, and stopping more than 2 months...